Skip to Content

Generic Soolantra Availability

Soolantra is a brand name of ivermectin topical, approved by the FDA in the following formulation(s):

SOOLANTRA (ivermectin - cream;topical)

Has a generic version of Soolantra been approved?

No. There is currently no therapeutically equivalent version of Soolantra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Soolantra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method for treating rosacea using oral or topical ivermectin
    Patent 5,952,372
    Issued: September 14, 1999
    Inventor(s): McDaniel; William Robert
    A method of treating rosacea in humans involving orally-administered or topically-applied ivermectin is disclosed. More specifically, oral ivermectin in a regimen of 200 micrograms per kilogram body weight per dose for 2 or 3 consecutive doses at least 3 and not more than 7 days apart as the preferred regimen or, alternatively, topical ivermectin compounded to a 2% concentration by weight in a cream, lotion, or gel carrier vehicle is administered as an effective treatment for all clinical stages and signs of rosacea in affected persons.
    Patent expiration dates:
    • September 18, 2018
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Method of treatment of rosacea
    Patent 6,133,310
    Issued: October 17, 2000
    Inventor(s): Parks; L. Dean
    A method of treatment of acne rosacea consists of the application, in the form of either a lotion or a cream, constituting a mixture of a therapeutically effective amount of invermectin in water, in the case of the lotion, and invermectin and a pharmaceutically acceptable carrier, in the case of the cream. Application to the affected area occurs daily for a period of one week and, thereafter, two to four times per month for a period of up to one year.
    Patent expiration dates:
    • April 26, 2019
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 7,550,440
    Issued: June 23, 2009
    Inventor(s): Manetta; Vincent & Watkins; Gary R.
    Assignee(s): Galderma S.A.
    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
    Patent expiration dates:
    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,080,530
    Issued: December 20, 2011
    Inventor(s): Manetta; Vincent & Watkins; Gary R.
    Assignee(s): Galderma S.A.
    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
    Patent expiration dates:
    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,093,219
    Issued: January 10, 2012
    Inventor(s): Manetta; Vincent & Watkins; Gary R.
    Assignee(s): Galderma S.A.
    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
    Patent expiration dates:
    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,415,311
    Issued: April 9, 2013
    Assignee(s): Galderma S.A.
    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
    Patent expiration dates:
    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,470,788
    Issued: June 25, 2013
    Assignee(s): Galderma S.A.
    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
    Patent expiration dates:
    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,815,816
    Issued: August 26, 2014
    Assignee(s): Galderma S.A.
    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
    Patent expiration dates:
    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Treatment of papulopustular rosacea with ivermectin
    Patent 9,089,587
    Issued: July 28, 2015
    Assignee(s): Galderma S.A.
    Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Patent expiration dates:
    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Treatment of inflammatory lesions of rosacea with ivermectin
    Patent 9,233,117
    Issued: January 12, 2016
    Assignee(s): Galderma S. A.
    Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.
    Patent expiration dates:
    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Treatment of papulopustular rosacea with ivermectin
    Patent 9,233,118
    Issued: January 12, 2016
    Assignee(s): Galderma S.A.
    Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Patent expiration dates:
    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 19, 2017 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide